Cell Therapy and CAR-T Development Services

Crown Bioscience provides a full suite of in vitro, ex vivo, and in vivo models for CAR-T and cell therapy development. These include 3D tumor spheroids, patient-derived organoids, patient-derived xenografts (PDX), and humanized mouse models. Together, these systems replicate the tumor-immune microenvironment, allowing for accurate assessment of efficacy, persistence, and toxicity before clinical trials.

CAR-T efficacy and persistence are assessed using functional immune assays, cytokine profiling, and live-cell imaging in both 3D tumor models and humanized in vivo systems. These approaches measure tumor killing, T-cell activation, and long-term immune memory to predict clinical outcomes more reliably.

Humanized mouse models are essential for studying human immune-tumor interactions in a controlled environment. Crown Bioscience’s humanized models enable researchers to evaluate CAR-T trafficking, tumor infiltration, and cytokine release, providing critical insights into safety, potency, and durability before entering clinical trials.

Unlike conventional cell-based assays, Crown Bioscience’s translational platforms combine human-relevant 3D systems with in vivo validation. This integrated approach recreates the tumor microenvironment, reduces reliance on oversimplified models, and produces clinically predictive data that de-risk CAR-T and cell therapy development.

Yes. Crown Bioscience’s preclinical platforms support combination therapy evaluation, allowing researchers to test CAR-T therapies with checkpoint inhibitors, targeted drugs, or immunomodulators. This helps identify synergistic effects, optimize dosing strategies, and accelerate the path to clinical translation.

Solid tumors present challenges for CAR-T therapies, including limited tumor infiltration and an immunosuppressive microenvironment. Crown Bioscience provides 3D tumor organoids, spheroids, and PDX models that accurately replicate solid tumor architecture, enabling the evaluation of T-cell trafficking, persistence, and tumor penetration in clinically relevant settings.

As a leading cell therapy CRO, Crown Bioscience offers end-to-end preclinical services—from target validation and potency testing to in vivo efficacy, safety, and biodistribution studies. Our platforms integrate functional immune assays, biomarker discovery, and translational analytics to support IND-enabling research for CAR-T, TCR-T, and NK cell therapies.

TCR-T (T-cell receptor-engineered) therapies are engineered immune cells that recognize intracellular tumor antigens presented by MHC molecules. Crown Bioscience supports TCR-T development through custom target validation assays, humanized immune models, and tumor organoid co-culture systems, enabling accurate evaluation of antigen recognition, cytotoxicity, and off-target effects.

Translational models help identify cytokine release, off-target toxicity, and immune overactivation early in development. Crown Bioscience’s humanized mouse models and 3D tumor systems allow precise measurement of cytokine dynamics and tissue-specific effects, providing predictive safety data that reduce clinical risk.

Yes. Crown Bioscience provides customized study designs tailored to each therapy type, including hematologic malignancies, solid tumors, and rare cancers. Our team can adapt models for autologous or allogeneic CAR-Ts, TCR-Ts, NK, and macrophage-based therapies, ensuring the platform mirrors the intended clinical context.